Authors
Adam Trickey, Margaret T May, Jorg-Janne Vehreschild, Niels Obel, M John Gill, Heidi M Crane, Christoph Boesecke, Sophie Patterson, Sophie Grabar, Charles Cazanave, Matthias Cavassini, Leah Shepherd, Antonella d'Arminio Monforte, Ard van Sighem, Mike Saag, Fiona Lampe, Vicky Hernando, Marta Montero, Robert Zangerle, Amy C Justice, Timothy Sterling, Suzanne M Ingle, Jonathan AC Sterne
Publication date
2017/8/1
Journal
The lancet HIV
Volume
4
Issue
8
Pages
e349-e356
Publisher
Elsevier
Description
Background
Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013.
Methods
We analysed data from 18 European and North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible for this analysis if they had started ART with three or more drugs between 1996 and 2010 and had at least 3 years of potential follow-up. We estimated adjusted (for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA at start of ART) all-cause and cause-specific mortality hazard ratios (HRs) for the first year after ART initiation and the second and third years after ART initiation in …
Scholar articles
A Trickey, MT May, JJ Vehreschild, N Obel, MJ Gill… - The lancet HIV, 2017